Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Feb;43(2):135-9.
doi: 10.1016/0026-0495(94)90234-8.

Successful islet allotransplantation in diabetic rats immunosuppressed with FK506: a functional and immunological study

W J Tze  1 , J Tai, S S Cheung, N Murase, T E Starzl
Affiliations

Successful islet allotransplantation in diabetic rats immunosuppressed with FK506: a functional and immunological study

W J Tze et al. Metabolism. 1994 Feb.

Abstract

The effect of a novel immunosuppressive agent, FK506, on fresh islet allografts was evaluated in diabetic rats across major histocompatibility complex (MHC) barriers with respect to the transplantation (TR) site, islet source, treatment regimen, and antidonor antibody (Ab) titers of the recipients after TR. The functional periods of Wistar (Wi) islets transplanted under kidney capsule (KC) or intraportally (IPo) and of a mixture of Wi and Lewis (Le) islets under KC or IPo in nonimmunosuppressed ACI rat recipients were 6.9 +/- 0.4 (n = 7), 6.4 +/- 0.5 (n = 7), 5.6 +/- 0.4 (n = 7), and 6.2 +/- 0.4 (n = 5) days, respectively. FK506 treatment at 1 mg/kg/d intramuscularly (IM) for 2 weeks (protocol I) following islet TR under KC and IPo significantly prolonged the allograft function to more than 71.8 +/- 11.3 (n = 10) and 161.7 +/- 18.6 (n = 11) days, respectively. Additional treatment with FK506 at 1 mg/kg/wk (protocol II) further increased the islet survival under KC to more than 212.6 +/- 22.3 (n = 8) days. With this FK506 treatment protocol, the Wi + Le mixed-islet allograft function was extended to more than 106.1 +/- 10.5 (n = 7) and 167.9 +/- 28.6 (n = 7) days under KC and IPo, respectively. Nephrectomy in 8/8 ACI rats with long-term-functioning Wi (n = 6) and Wi + Le (n = 2) islet allografts resulted in their return to hyperglycemia. Immunohistochemical staining showed abundant insulin-positive cells at the graft site, with small numbers of CD4- and CD8-positive cells present in the vicinity of the normal-appearing islets. Macrophages were not detected.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Figures

Fig 1
Fig 1
Serum glucose levels of ACI rats with long-term-functional IPo Wi islet allografts rendered diabetic by STZ injection (arrow) and then either retransplanted with fresh Wi islets IPo (▽, △) or under KC (□, ▷) or without retransplantation (○ ◁).
Fig 2
Fig 2
Mean cytotoxic Ab titers In ACI recipients of fresh Wi islet allograft under KC with (■, mean ± SEM, n = 7) and without (□, n = 12) FK506 treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sutherland DER, Chinn PL, Morrow CW. Transplantation of pancreatic islets. In: Gupta S, editor. Immunology of Clinical Experimental Diabetes. New York, NY: Plenum; 1984. pp. 147–246.
    1. Sima AAF, Zang W-X, Tze WJ, et al. Diabetic neuropathy in the streptozolocin diabetic rat and the effect of allogeneic islet cell transplantation. A morphometric analysis. Diabetes. 1988;37:1129–1136. - PubMed
    1. Thomson AW. Interspecies comparison of the immunosuppressive efficacy and safety of FK506. Transplant Proc. 1990;22(suppl I):100–105. - PubMed
    1. Tze WJ, Tai J, Cheung SSC, et al. FK506—An effective immunosuppressant in achieving long-term functional islet allograft in diabetic rats. Transplant Proc. 1992;24:1034–1036. - PMC - PubMed
    1. Yasunami Y, Schinichiroh R, Kameis T. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. Transplantation. 1990;49:682–686. - PubMed

Publication types